Nabriva Therapeutics AG (NBRV)
(Delayed Data from NSDQ)
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.16 USD
+0.01 (0.47%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.16 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.
Nabriva Soars on Agreement With Merck to Distribute Sivextro
by Zacks Equity Research
Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.
Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
Nabriva's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
Implied Volatility Surging for Nabriva (NBRV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)
by Zacks Equity Research
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Lineage Cell (LCTX) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Lineage Cell's (LCTX) Q1 earnings call, investor focus will be on its progress with the pipeline candidate OpRegen, currently being developed for treating dry AMD, as well as other pipeline updates.
Why Nabriva Therapeutics (NBRV) Stock Might be a Great Pick
by Zacks Equity Research
Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session
by Zacks Equity Research
Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Idera Completes Recruitment in Late-Stage Melanoma Study
by Zacks Equity Research
Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.
AMAG Q4 Loss Wider Than Expected, Revenues Beat Estimates
by Zacks Equity Research
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
Will Nabriva Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
by Zacks Equity Research
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4
by Zacks Equity Research
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
Is the Options Market Predicting a Spike in Nabriva (NBRV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.
Melinta (MLNT) Announces Preliminary Product Sales for Q2
by Zacks Equity Research
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin
by Zacks Equity Research
The EMA endorses Nabriva Therapeutics' (NBRV) marketing application for both the intravenous and oral formulations of lefamulin to treat adult patients with community-acquired pneumonia.
Do Options Traders Know Something About Nabriva Therapeutics (NBRV) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.
Nabriva Therapeutics (NBRV) in Focus: Stock Moves 7.5% Higher
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Nabriva Therapeutics (NBRV) Jumps: Stock Rises 6.7%
by Zacks Equity Research
Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Implied Volatility Surging for Nabriva Therapeutics plc (NBRV) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.
Nabriva Therapeutics (NBRV) Enters Oversold Territory
by Zacks Equity Research
Nabriva Therapeutics plc (NBRV) has been on a bit of a cold streak lately
Is the Options Market Predicting a Spike in Nabriva Therapeutics (NBRV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nabriva Therapeutics (NBRV) stock based on the movements in the options market lately.